You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Twitter Demographics
Mendeley readers
Attention Score in Context
| Title |
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer
|
|---|---|
| Published in |
OncoTargets and therapy, July 2013
|
| DOI | 10.2147/ott.s44906 |
| Pubmed ID | |
| Authors |
Peter Siegel, Rose, Annis, Maric |
| Abstract |
Molecularly targeted therapies are rapidly growing with respect to their clinical development and impact on cancer treatment due to their highly selective anti-tumor action. However, many aggressive cancers such as triple-negative breast cancer (TNBC) currently lack well-defined therapeutic targets against which such agents can be developed. The identification of tumor-associated antigens and the generation of antibody drug-conjugates represent an emerging area of intense interest and growth in the field of cancer therapeutics. Glycoprotein non-metastatic b (GPNMB) has recently been identified as a gene that is over-expressed in numerous cancers, including TNBC, and often correlates with the metastatic phenotype. In breast cancer, GPNMB expression in the tumor epithelium is associated with a reduction in disease-free and overall survival. Based on these findings, glembatumumab vedotin (CDX-011), an antibody-drug conjugate that selectively targets GPNMB, is currently being investigated in clinical trials for patients with metastatic breast cancer and unresectable melanoma. This review discusses the physiological and potential pathological roles of GPNMB in normal and cancer tissues, respectively, and details the clinical advances and challenges in targeting GPNMB-expressing malignancies. |
Twitter Demographics
The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 96 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 18% |
| Researcher | 17 | 18% |
| Student > Ph. D. Student | 15 | 16% |
| Student > Postgraduate | 10 | 10% |
| Other | 7 | 7% |
| Other | 11 | 11% |
| Unknown | 19 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 24% |
| Agricultural and Biological Sciences | 15 | 16% |
| Medicine and Dentistry | 12 | 13% |
| Immunology and Microbiology | 7 | 7% |
| Neuroscience | 5 | 5% |
| Other | 12 | 13% |
| Unknown | 22 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2017.
All research outputs
#6,259,595
of 22,715,151 outputs
Outputs from OncoTargets and therapy
#297
of 2,927 outputs
Outputs of similar age
#52,943
of 194,642 outputs
Outputs of similar age from OncoTargets and therapy
#10
of 42 outputs
Altmetric has tracked 22,715,151 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,927 research outputs from this source. They receive a mean Attention Score of 2.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,642 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.